New combo attack on stubborn leukemia: chemo then transplant
NCT ID NCT04375631
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests a two-step approach for people with acute myeloid leukemia or related blood cancers that have returned or not responded to treatment. First, patients receive intensive chemotherapy (CLAG-M or FLAG-Ida) followed immediately by a reduced-intensity stem cell transplant from a donor. The goal is to find the safest dose of total body irradiation given as part of this regimen and to see if the approach can prevent graft failure and disease progression. About 120 adults are being enrolled at Fred Hutchinson Cancer Center.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- cladribine, cytarabine, filgrastim, mitoxantrone, idarubicin, fludarabine, cyclophosphamide, cyclosporine, mycophenolate mofetil, total body irradiation
- What this could lead to
- If successful, this could point toward a more effective way to treat aggressive blood cancers that have not responded to standard therapy, potentially improving remission rates.
- What could go wrong
- This is a very early phase 1 study, so the main goal is safety and dosing, not proof of effectiveness. There is a risk of serious side effects including graft-versus-host disease, infection, and organ damage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fred Hutch/University of Washington Cancer Consortium
RECRUITINGSeattle, Washington, 98109, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug aims to wake up immune system against Hard-to-Treat leukemia
- New drug combo aims to outsmart resistant leukemia
- Gentler chemo approach shows promise for tough blood cancers in older patients
- Selective immune cell removal may tame transplant complications
- Promising combo for IDH1 leukemia hits early snag – trial stopped
- Engineered immune cells take aim at Hard-to-Treat leukemia